The impact of COVID-19 monoclonal antibodies on clinical outcomes: A retrospective cohort study

{ 'indexed': { 'date-parts': [[2022, 10, 15]], 'date-time': '2022-10-15T17:42:43Z', 'timestamp': 1665855763377}, 'reference-count': 0, 'publisher': 'Oxford University Press (OUP)', 'license': [ { 'start': { 'date-parts': [[2022, 10, 15]], 'date-time': '2022-10-15T00:00:00Z', 'timestamp': 1665792000000}, 'content-version': 'am', 'delay-in-days': 0, 'URL': 'https://academic.oup.com/pages/standard-publication-reuse-rights'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'abstract': '<jats:title>Abstract</jats:title>\n' ' <jats:sec>\n' ' <jats:title>Disclaimer</jats:title>\n' ' <jats:p>In an effort to expedite the publication of articles, AJHP is ' 'posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have ' 'been peer-reviewed and copyedited, but are posted online before technical formatting and ' 'author proofing. These manuscripts are not the final version of record and will be replaced ' 'with the final article (formatted per AJHP style and proofed by the authors) at a later ' 'time.</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Purpose</jats:title>\n' ' <jats:p>Despite progress in the treatment of coronavirus disease 2019 ' '(COVID-19), including the development of monoclonal antibodies (mAbs), more clinical data to ' 'support the use of mAbs in outpatients with COVID-19 is needed. This study is designed to ' 'determine the impact of bamlanivimab, bamlanivimab/etesevimab, or casirivimab/imdevimab on ' 'clinical outcomes within 30 days of COVID-19 diagnosis.</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Methods</jats:title>\n' ' <jats:p>A retrospective cohort study was conducted at a single academic ' 'medical center with 3 campuses in Manhattan, Brooklyn, and Long Island, NY. Patients 12 years ' 'of age or older who tested positive for COVID-19 or were treated with a COVID-19–specific ' 'therapy, including COVID-19 mAb therapies, at the study site between November 24, 2020, and ' 'May 15, 2021, were included. The primary outcomes included rates of emergency department (ED) ' 'visit, inpatient admission, intensive care unit (ICU) admission, or death within 30 days from ' 'the date of COVID-19 diagnosis.</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Results</jats:title>\n' ' <jats:p>A total of 1,344 mAb-treated patients were propensity matched to ' '1,344 patients with COVID-19 patients who were not treated with mAb therapy. Within 30 days ' 'of diagnosis, among the patients who received mAb therapy, 101 (7.5%) presented to the ED and ' '79 (5.9%) were admitted. Among the patients who did not receive mAb therapy, 165 (12.3%) ' 'presented to the ED and 156 (11.6%) were admitted (relative risk [RR], 0.61 [95% CI, ' '0.50-0.75] and 0.51 [95% CI, 0.40-0.64], respectively). Four mAb patients (0.3%) and 2.64 ' 'control patients (0.2%) were admitted to the ICU (RR, 01.51; 95% CI, 0.45-5.09). Six ' 'mAb-treated patients (0.4%) and 3.37 controls (0.3%) died and/or were admitted to hospice ' '(RR, 1.61; 95% CI, 0.54-4.83). mAb therapy in ambulatory patients with COVID-19 decreases the ' 'risk of ED presentation and hospital admission within 30 days of diagnosis.</jats:p>\n' ' </jats:sec>', 'DOI': '10.1093/ajhp/zxac295', 'type': 'journal-article', 'created': { 'date-parts': [[2022, 10, 15]], 'date-time': '2022-10-15T17:06:42Z', 'timestamp': 1665853602000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'The impact of COVID-19 monoclonal antibodies on clinical outcomes: A retrospective cohort study', 'prefix': '10.1093', 'author': [ { 'given': 'Arielle R', 'family': 'Nagler', 'sequence': 'first', 'affiliation': [ { 'name': 'The Ronald O. Perelman Department of Dermatology, NYU Grossman ' 'School of Medicine, New York , NY, USA'}]}, { 'given': 'Leora I', 'family': 'Horwitz', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Medicine and Department of Population Health, NYU ' 'Grossman School of Medicine, New York , NY, USA'}]}, { 'given': 'Simon', 'family': 'Jones', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Population Health, NYU Grossman School of ' 'Medicine, New York , NY, USA'}]}, { 'given': 'Christopher M', 'family': 'Petrilli', 'sequence': 'additional', 'affiliation': [{'name': 'NYU Grossman School of Medicine, New York , NY, USA'}]}, { 'given': 'Eduardo', 'family': 'Iturrate', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Medicine, NYU Grossman School of Medicine, New ' 'York , NY, USA'}]}, { 'given': 'Jennifer L', 'family': 'Lighter', 'sequence': 'additional', 'affiliation': [ { 'name': 'Division of Pediatric Infectious Diseases, Department of ' 'Pediatrics, NYU Grossman School of Medicine, New York , NY, ' 'USA'}]}, { 'given': 'Michael', 'family': 'Phillips', 'sequence': 'additional', 'affiliation': [ { 'name': 'Division of Infectious Disease, Department of Medicine, NYU ' 'Grossman School of Medicine, New York , NY, USA'}]}, { 'given': 'Brian P', 'family': 'Bosworth', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Medicine, NYU Grossman School of Medicine, New ' 'York , NY, andNYU Langone Health, New York, NY, USA'}]}, { 'given': 'Bruce', 'family': 'Polsky', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Medicine, NYU Long Island School of Medicine, New ' 'York , NY, USA'}]}, { 'given': 'Frank M', 'family': 'Volpicelli', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Medicine, NYU Grossman School of Medicine, New ' 'York , NY, USA'}]}, { 'given': 'Isaac', 'family': 'Dapkins', 'sequence': 'additional', 'affiliation': [{'name': 'Family Health Centers at NYU Langone, Brooklyn , NY, USA'}]}, { 'given': 'Anand', 'family': 'Viswanathan', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Medicine, NYU Grossman School of Medicine, New ' 'York , NY, USA'}]}, { 'given': 'Fritz', 'family': 'François', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Medicine, NYU Grossman School of Medicine, New ' 'York , NY, and NYU Langone Health, New York, NY, USA'}]}, { 'given': 'Gary', 'family': 'Kalkut', 'sequence': 'additional', 'affiliation': [ { 'name': 'Division of Infectious Disease, Department of Medicine, NYU ' 'Grossman School of Medicine, New York , NY, and NYU Langone ' 'Health, New York, NY, USA'}]}], 'member': '286', 'published-online': {'date-parts': [[2022, 10, 15]]}, 'container-title': 'American Journal of Health-System Pharmacy', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://academic.oup.com/ajhp/advance-article-pdf/doi/10.1093/ajhp/zxac295/46539445/zxac295.pdf', 'content-type': 'application/pdf', 'content-version': 'am', 'intended-application': 'syndication'}, { 'URL': 'https://academic.oup.com/ajhp/advance-article-pdf/doi/10.1093/ajhp/zxac295/46539445/zxac295.pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 10, 15]], 'date-time': '2022-10-15T17:06:43Z', 'timestamp': 1665853603000}, 'score': 1, 'resource': { 'primary': { 'URL': 'https://academic.oup.com/ajhp/advance-article/doi/10.1093/ajhp/zxac295/6761664'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 10, 15]]}, 'references-count': 0, 'URL': 'http://dx.doi.org/10.1093/ajhp/zxac295', 'relation': {}, 'ISSN': ['1079-2082', '1535-2900'], 'subject': ['Health Policy', 'Pharmacology'], 'published': {'date-parts': [[2022, 10, 15]]}}